The bacterial infections drug developer, backed by Alphabet, Partners Healthcare, GlaxoSmithKline, Merck & Co and Lundbeck, has gone public.
Spero Therapeutics, a US-based biopharmaceutical company backed by corporates Alphabet, Partners Healthcare, GlaxoSmithKline, Merck & Co and Lundbeck, has raised $77m in its initial public offering.
The company issued 5 million shares on the Nasdaq Global Select Market priced at $14.00 each, at the foot of the IPO’s $14 to $16 range. The underwriters have a 30-day option to buy another 825,000 shares, which would lift the size of the offering to $88.6m.
Spero is working on drugs that…
